Cathepsin B Inhibitor CA-074: Practical Guidance for Research Use

What This Product Solves

Cathepsin B is a cysteine protease implicated in critical biological processes including antigen processing, apoptosis, and metastatic progression in cancer. Selective inhibition of cathepsin B activity is essential for dissecting its specific roles without confounding effects from related cathepsins. Cathepsin B inhibitor CA-074 (SKU A1926) is a small molecule tool validated for potent and highly selective inhibition of cathepsin B, with a Ki of 2–5 nM and >10,000-fold selectivity over cathepsins H and L (source: product_spec). This specificity enables researchers to interrogate cathepsin B's function in cancer metastasis, neurotoxicity reduction, and immune response modulation, with minimal off-target interference. CA-074 is routinely applied in studies of inhibition of cathepsin B in breast cancer bone metastasis and in neurodegeneration models where neurotoxicity reduction via cathepsin B inhibition is investigated.

For an in-depth analysis of CA-074’s application in cancer and neurodegeneration research, see the internal review CA-074: Selective Cathepsin B Inhibitor for Cancer and Neurodegeneration, which details its mechanistic specificity and translational research support. Workflow-oriented users may consult Strategic Cathepsin B Inhibition: Unleashing Translational Research for protocol integration strategies.

Protocol Parameters

• assay: Cathepsin B enzymatic inhibition assay | value_with_unit: Ki = 2–5 nM | applicability: Quantitative evaluation of CA-074 potency against cathepsin B | rationale: Establishes effective dose range for selective inhibition in in vitro enzymology or cell-based assays | source_type: product_spec
• assay: Cathepsin H/L selectivity testing | value_with_unit: Ki = 40–200 μM | applicability: Selectivity profiling to confirm minimal off-target inhibition | rationale: Ensures that observed biological effects are due to cathepsin B inhibition, not related proteases | source_type: product_spec
• assay: Solubility assessment | value_with_unit: ≥19.17 mg/mL in DMSO, ≥31.3 mg/mL in ethanol, ≥5.91 mg/mL in water (ultrasonic assistance) | applicability: Preparation of concentrated stock solutions for in vitro and in vivo experiments | rationale: Guides solvent choice and stock solution preparation protocols | source_type: product_spec
• assay: Cell viability (HUVEC cytotoxicity) | value_with_unit: 10 mM shows negligible cytotoxicity | applicability: Selection of non-toxic working concentrations in cell culture | rationale: Confirms suitability for use in sensitive cell types | source_type: product_spec
• assay: Storage and stability | value_with_unit: Store at -20°C; prepare solutions for short-term use only | applicability: Maintains compound integrity and reproducibility | rationale: Prevents degradation and potency loss during storage and handling | source_type: product_spec

Workflow Setup and QC Checklist

• Stock Preparation: Dissolve CA-074 in DMSO to achieve high-concentration stocks (≥19.17 mg/mL), or use ethanol/water (ultrasonic assistance) as needed for experimental compatibility (source: product_spec).
• Aliquoting and Storage: Immediately aliquot stock solutions after preparation and store at -20°C. Avoid repeated freeze-thaw cycles to maintain activity.
• Working Solution Dilution: Prepare fresh working solutions just prior to use, preferably within hours, to prevent hydrolysis or oxidation. For aqueous dilutions, sonicate if necessary to assist solubilization.
• Negative Controls: Include vehicle-only and non-target protease controls to attribute observed effects to cathepsin B inhibition.
• QC Verification: Confirm solution clarity and absence of precipitation. Where possible, verify compound identity and concentration by analytical methods (e.g., HPLC).
• Assay Validation: Use positive controls (e.g., recombinant cathepsin B activity) to validate inhibition kinetics and confirm selectivity profile.

Common Failure Modes and Fixes

• Incomplete Dissolution: If CA-074 does not fully dissolve in water, use ultrasonic assistance or switch to DMSO/ethanol as the primary solvent as per solubility data (product_spec).
• Loss of Activity: Degraded or improperly stored compound can result in reduced inhibition; always prepare solutions fresh and minimize exposure to repeated freeze-thaw cycles.
• Off-Target Effects: Using excessive concentrations may cause partial inhibition of cathepsin H or L; adhere to recommended dosing (Ki for cathepsin B is 2–5 nM, selectivity drops at high μM range).
• Precipitation in Culture Media: Ensure compatibility of CA-074 with media components; filter solutions if necessary and confirm stability during the assay window.

Scope and Limitations

• CA-074 is highly selective for cathepsin B and is not suitable for studies requiring broad-spectrum cysteine protease inhibition.
• Due to limited long-term stability in solution, it is not recommended for protocols requiring extended incubation or storage of working solutions.
• Concentration-dependent selectivity must be maintained to avoid off-target activity, especially in systems expressing multiple cathepsins.
• The compound is validated for in vitro and preclinical in vivo research; it is not intended for clinical or diagnostic use.
• Effects on other biological systems or in poorly characterized models should be interpreted cautiously, as current evidence is restricted to cancer metastasis, neurodegeneration, and immune modulation pathways (related review).

Conclusion

Cathepsin B inhibitor CA-074 is an established and reliable tool for researchers requiring precise, nanomolar-level inhibition of cathepsin B. Its validated selectivity profile, solubility characteristics, and clear protocol parameters support its application in studies of cancer metastasis, neurotoxicity reduction, and immune response modulation. Careful adherence to workflow recommendations and quality control practices ensures reproducibility and minimizes experimental artifacts. For detailed specifications and ordering information, refer to the APExBIO product page.